To all of the Dentists, Nurses, Laboratory Scientists, Orthopedic surgeons, and Physiotherapists attending congress – with the purchase of the Pro+ add-on, you will gain access to exclusive online only sessions within each of your fields—both live and on-demand.
Visit the Congress website to further explore your options, review which sessions are included in both the virtual registration and the Pro+ add-on, and find out more about the other perks you will be able to enjoy:
WFH 2022 World Congress Virtual Attendees
Virtual attendees will be able to access live and on demand content—and enjoy many networking opportunities—through our Virtual Platform. To learn more about the features and functionalities of our platform, watch the following short video:
WFH 2022 World Congress App now available!
Make sure to download the Congress mobile application, by Event App, to have quick access to the program, speaker information, floorplan and more. Scan the QR code below with your smartphone to download the app.
Use event app code: wfh22
Alternatively, you can click below links to download the app:
WFH 2022 Medical Program Committee announces a third late-breaking session to its scientific lineup at the World Congress!
The WFH 2022 World Congress will feature three late-breaking science sessions over the three days. The late breakers include new data in clinical trial research:
Late-breaking Clinical Research 1: Monday, May 9 – 13:30 to 14:30
- A Phase 1 Sequential Pharmacokinetic (PK) Evaluation of Octocog Alfa, Rurioctocog Alfa Pegol, and Efanesoctocog Alfa in Severe Hemophilia A
- Exploratory analyses of healthy liver biopsies and a single case of parotid acinar cell carcinoma do not identify a role for Valactogene Roxaparvovec vector in altering cell growth
- Immune suppression following Gene Therapy in Hemophilia Late-Breaking Science 2: Hypertension: Local, Global and Pandemic Impacts
Late-Breaking Clinical Research 2: Tuesday, May 10 – 13:30 to 14:30
- Health-related quality of life over two years following valoctocogene roxaparvovec adeno-associated virus gene transfer for severe hemophilia A: Results from GENEr8-1
- Rondoraptivon pegol (BT200) for the treatment of type 2B von Willebrand disease
- Gene Editing for Rare Diseases: Transthyretin-Amyloidosis and Hemophilia B
Late-Breaking Clinical Research 3: Wednesday, May 11 – 13:30 to 14:30
- Pain adversely impacts quality of life in people with hemophilia: The Perceptions of Pain in Hemophilia study
- Use of magnetic resonance imaging (MRI) and Hemophilia Joint Health Score (HJHS) to assess joint status after two years of a personalized rehabilitation program in patients with severe hemophilia with inhibitor (PWHI) on long-term prophylaxis with activated prothrombin complex concentrate (aPCC)
- Human Liver Biopsy Analysis showed interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A
Joining in person?
On-site registrations will be accepted at the Palais des congrès as of 7:30 a.m. on Sunday, May 8 at the registration desk located in the exhibition hall (room 220BCD).